Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. Therapeutic areas include: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina.

In 2020, Johnson & Johnson declared racism a public health threat and launched Our Race to Health Equity (ORTHE) in the U.S. – a five-year, $100 million commitment. Consistent with Our Credo, our commitment to diversity, equity and inclusion (DEI) in the workplace, and our legacy of tackling the most pressing health challenges, ORTHE is J&J’s commitment to help close the racial health gap so the color of your skin does not determine your access to care, quality of care or health outcomes. We’re changing the way that we work to instill a racial health equity mindset and skillset across our company and using our scale and size to catalyze systemic change across the healthcare industry.

As part of this commitment, our Johnson & Johnson Research & Development team initiated the Johnson & Johnson Scholars of Diversity Engagement Program (J&J SDEP) to build relationships with exceptional Ph.D. students, medical students, Pharm.D. students, and post-doctoral researchers from underrepresented groups as defined in the eligibility section. We aim to contribute to shaping their careers and to bringing greater visibility to our job opportunities by providing industry exposure and mentorship in partnership with R&D leaders at J&J.